drugset / Trial / NCT00656474

Efficacy Study of GLYC-101 to Evaluate Outcomes After Post-laser Ablation

NCT00656474

Phase 1/2 Completed 12 enrolled TR Therapeutics
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Study is intended to evaluate safety and efficacy parameters in patients treated with GLYC-101 gel or placebo after laser ablation.

Timeline

Start
2008-03
Primary completion
2008-04
Completion
2008-08

Drugs

EvaluationDrugModalityDoseRoute
Subject beta-glucan Other / unclassified 1 % Topical

Indications

No indication recorded.